The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Colchicine poisoning: the dark side of an ancient drug
Abstract
INTRODUCTION: Colchicine is used mainly for the treatment and prevention of gout and for familial Mediterranean fever (FMF). It has a narrow therapeutic index, with no clear-cut distinction between nontoxic, toxic, and lethal doses, causing substantial confusion among clinicians. Although colchicine poisoning is sometimes intentional, unintentional toxicity is common and often associated with a poor outcome. METHODS: We performed a systematic review by searching OVID MEDLINE between 1966 and January 2010. The search strategy included "colchicine" and "poisoning" or "overdose" or "toxicity" or "intoxication." TOXICOKINETICS: Colchicine is readily absorbed after oral administration, but undergoes extensive first-pass metabolism. It is widely distributed and binds to intracellular elements. Colchicine is primarily metabolized by the liver, undergoes significant enterohepatic re-circulation, and is also excreted by the kidneys. THERAPEUTIC AND TOXIC DOSES: The usual adult oral doses for FMF is 1.2-2.4 mg/day; in acute gout 1.2 mg/day and for gout prophylaxis 0.5-0.6 mg/day three to four times a week. High fatality rate was reported after acute ingestions exceeding 0.5 mg/kg. The lowest reported lethal doses of oral colchicine are 7-26 mg. DRUG INTERACTIONS: CYP 3A4 and P-glycoprotein inhibitors, such as clarithromycin, erythromycin, ketoconazole, ciclosporin, and natural grapefruit juice can increase colchicine concentrations. Co-administration with statins may increase the risk of myopathy. MECHANISMS OF TOXICITY: Colchicine's toxicity is an extension of its mechanism of action - binding to tubulin and disrupting the microtubular network. As a result, affected cells experience impaired protein assembly, decreased endocytosis and exocytosis, altered cell morphology, decreased cellular motility, arrest of mitosis, and interrupted cardiac myocyte conduction and contractility. The culmination of these mechanisms leads to multi-organ dysfunction and failure. REPRODUCTIVE TOXICOLOGY AND LACTATION: Colchicine was not shown to adversely affect reproductive potential in males or females. It crosses the placenta but there is no evidence of fetal toxicity. Colchicine is excreted into breast milk and considered compatible with lactation. CLINICAL FEATURES: Colchicine poisoning presents in three sequential and usually overlapping phases: 1) 10-24 h after ingestion - gastrointestinal phase mimicking gastroenteritis may be absent after intravenous administration; 2) 24 h to 7 days after ingestion - multi-organ dysfunction. Death results from rapidly progressive multi-organ failure and sepsis. Delayed presentation, pre-existing renal or liver impairment are associated with poor prognosis. 3) Recovery typically occurs within a few weeks of ingestion, and is generally a complete recovery barring complications of the acute illness. DIAGNOSIS: History of ingestion of tablets, parenteral administration, or consumption of colchicine-containing plants suggest the diagnosis. Colchicine poisoning should be suspected in patients with access to the drug and the typical toxidrome (gastroenteritis, hypotension, lactic acidosis, and prerenal azotemia). MANAGEMENT: Timely gastrointestinal decontamination should be considered with activated charcoal, and very large, recent (<60 min) ingestions may warrant gastric lavage. Supportive treatments including administration of granulocyte colony-stimulating factor are the mainstay of treatment. Although a specific experimental treatment (Fab fragment antibodies) for colchicine poisoning has been used, it is not commercially available. CONCLUSION: Although colchicine poisoning is relatively uncommon, it is imperative to recognize its features as it is associated with a high mortality rate when missed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Transfer of Drugs and Other Chemicals Into Human Milk
Committee on Drugs (2001) · Pediatrics · doi:10.1542/peds.108.3.776 · Cited by 1,256
Transfer of drugs and other chemicals into human milk
Roberts, R., Blumer, J. L., Gorman, R. L., Lambert, G. H., Rumack, B. H., SNODGRASS, W. T., Bennett, D. R., ', J. C., Petricciani, J. C., Licata, S., et al. (1989) · PEDIATRICS · Cited by 503
Colchicine Myopathy and Neuropathy
Kuncl, R. W., Duncan, G., Watson, D., Alderson, K., Rogawski, M. A., & Peper, M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706183162502 · Cited by 427
Ben-Chetrit, E., & Levy, M. (1998) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(98)80028-0 · Cited by 354
Terkeltaub, R. A. (2009) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.08.006 · Cited by 299
Colchicine Treatment for Recurrent Pericarditis: A Decade of Experience
Adler, Y., Finkelstein, Y., Guindo, J., Rodriguez de la Serna, A., Shoenfeld, Y., Bayes-Genis, A., Sagie, A., Bayes de Luna, A., & Spodick, D. H. (1998) · Circulation · doi:10.1161/01.cir.97.21.2183 · Cited by 242
Self-citationLong‐term colchicine treatment in children with familial mediterranean fever
Zemer, D., Livneh, A., Danon, Y. L., Pras, M., & Sohar, E. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340806 · Cited by 240
Treatment of Severe Colchicine Overdose with Colchicine-Specific Fab Fragments
Baud, F. J., Sabouraud, A., Vicaut, E., Taboulet, P., Lang, J., Bismuth, C., Rouzioux, J. M., & Scherrmann, J.-M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321004 · Cited by 237
Wallace, S. L., Omokoku, B., & Ertel, N. H. (1970) · The American Journal of Medicine · doi:10.1016/0002-9343(70)90043-4 · Cited by 161
Colchicine intoxication: Clinical pharmacology, risk factors, features, and management
Putterman, C., Ben‐Chetrit, E., Caraco, Y., & Levy, M. (1991) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(91)90003-i · Cited by 153
Cited by
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Dhyani, P., Quispe, C., Sharma, E., Bahukhandi, A., Sati, P., Attri, D. C., Szopa, A., Sharifi-Rad, J., Docea, A. O., Mardare, I., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02624-9 · Cited by 483
Mechanism of Action of Colchicine in the Treatment of Gout
Dalbeth, N., Lauterio, T. J., & Wolfe, H. R. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.07.017 · Cited by 416
Drosos, G. C., Vedder, D., Houben, E., Boekel, L., Atzeni, F., Badreh, S., Boumpas, D. T., Brodin, N., Bruce, I. N., González-Gay, M. Á., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221733 · Cited by 406
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
McLoughlin, E. C., & O’Boyle, N. M. (2020) · Pharmaceuticals · doi:10.3390/ph13010008 · Cited by 316
Metadata
- Authors
- Finkelstein, Y., Aks, S. E., Hutson, J. R., Juurlink, D. N., Nguyen, P., Dubnov-Raz, G., Pollak, U., Koren, G., & Bentur, Y.
- Venue
- Clinical Toxicology
- Publisher
- Informa UK Limited
- Published
- 2010-06
- Volume
- 48
- Issue
- 5
- Pages
- 407-414
- ISSN
- 0009-9309 (ISSN-L)
- 1556-3650
- 1556-9519
- OpenAlex
- W2146730043
- Cited by
- 589
- References
- 34
- FWCI
- 19.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colchicine poisoning: the dark side of an ancient drug. https://app.cochat.ai/papers/10.3109/15563650.2010.495348
- The paper
- Finkelstein, Y., Aks, S. E., Hutson, J. R., Juurlink, D. N., Nguyen, P., Dubnov-Raz, G., Pollak, U., Koren, G., & Bentur, Y. (2010). Colchicine poisoning: the dark side of an ancient drug. Clinical Toxicology. https://doi.org/10.3109/15563650.2010.495348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.